STAT+: Pharmalittle: We’re reading about Mark Cuban eyeing rare disease drugs, a ketamine gold rush, and more

Cost Plus Drugs plans to expand from its generics business into custom-made medicines for rare diseases. The company says its plant can quickly switch among small batches, enabling experimental treatments for individuals or very small patient groups. Meanwhile, Sandoz's plant in Kundl, Austria, Europe's only fully integrated penicillin facility, faces an uncertain future as China supplies the same antibiotics and active ingredients to the European market at lower cost.